Business
The pharmaceutical company Celgene Corp. has agreed to pay $280 million to settle a federal lawsuit alleging it committed fraud promoting two cancer drugs for unapproved purposes.
July 25, 2017
Amgen Inc. will pay $13.4 billion for a blockbuster psoriasis drug from Celgene Corp.
Aug. 26, 2019
Drugmakers, whose industry pricing faced renewed scorn this month from President Trump, have been taking advantage of the GOP tax overhaul he signed last year to buy back shares of their own underperforming stocks.
May 28, 2018
MemorialCare Health System buys headquarters in Costa Mesa
Feb. 3, 2013
Drugmaker Celgene Corp. agreed to invest an additional $30 million in a cancer-fighting start-up that’s majority owned by Los Angeles biotech entrepreneur Dr.
Jan. 6, 2019
Celgene Corp. agreed to buy San Diego firm Impact Biomedicines for $1.1 billion upfront to gain an experimental blood cancer treatment.
Jan. 8, 2018
Bristol-Myers Squibb Co. agreed to acquire Celgene Corp. in a record $74-billion deal that would unite two drugmakers battling for advantage in a crowded market for innovative cancer treatments.
Jan. 3, 2019
Maker of thalidomide is expected to get two treatments Okd in the next year, including one for a type of cancer.
May 24, 2005
Drug maker Celgene Corp. has agreed to acquire Pharmion Corp. for $72 a share in a cash-and-stock deal valued at $2.9 billion, the companies said Sunday.
Nov. 19, 2007
Cancer drug maker Celgene said it will buy Receptos for $7.32 billion in cash, gaining a drug Receptos is studying as a treatment for multiple sclerosis and ulcerative colitis.
July 14, 2015